Anti-Obesity

Danish Drugmaker To Invest $6 Billion To Boost Anti-Obesity Drug Output

Danish drugmaker Novo Nordisk said Friday it would invest 42 billion kroner ($6 billion) to expand manufacturing facilities in efforts to meet massive demand for its anti-diabetes and anti-obesity treatments.Sales of the Ozempic and Wegovy treatments have made Novo Nordisk